Generer rapport
Ferring Pharmaceuticals A/S
Amager Strandvej 405, 2770 Kastrup, CVR 16313440
Virksomhedsform
Aktieselskab
Etableret
1992
Størrelse
Store
Ansatte
559
Omsætning
1.261
MDKK
Bruttofortj.
646
MDKK
Primært resultat (EBIT)
67
MDKK
Årets resultat
52
MDKK
Egenkapital
122
MDKK
annonce
Flere nøgletal og analyser?
Med en Bisbase Premium konto får du flere nøgletal for både virksomheder, koncerner og brancher samt adgang til eksklusive brancher indeholdende virksomheder nøje sammensat af eksperter. Og vil du lave dine egne analyser kan du også det! Det tager få minutter at få adgang - og det behøver ikke at koste dig noget!
Rang Årets resultat
Rang i branche
4/360
"Top 10%"
Rang i Danmark
2.920/343.294
"Top 10%"
Direktion top 3
| Jan Peutzfeldt 2 | CEO |
| Kim Fonager Jensen 2 | Direktør |
| Klaus Grønbæk Jakobsen 4 | Direktør |
Bestyrelse top 3
| Marianne Kock 4 | Bestyrelsesformand |
| Dag Frederik Arfst Paulsen 1 | Bestyrelsesmedlem |
| Jean-Frederic Paulsen 1 | Bestyrelsesmedlem |
Legale ejere top 3
| 100% | Ferring B.V. | NL |
Tegningsregler
Selskabet tegnes af to bestyrelsesmedlemmer i forening eller af et bestyrelsesmedlem i forening med en direktør eller af to direktører i forening
Stamoplysninger baseret på CVR
| Navn | Ferring Pharmaceuticals A/S |
| CVR | 16313440 |
| Adresse | Amager Strandvej 405, 2770 Kastrup |
| Branche | Forskning og eksperimentel udvikling indenfor bioteknologi [721100] |
| Etableret | 01-08-1992 (31 år) |
| Første regnskabsperiode | 01-08-1992 til 31-12-1993 |
| Virksomhedsform | Aktieselskab |
| Antal ansatte | 654 (årsværk:601) |
| Reklamebeskyttelse | Nej |
| Revisor | Deloitte Statsautoriseret Revisionspartnerselskab siden 01-01-2014 |
| Regnskabsperiode | 01-01 til 31-12 |
| Bankforbindelse | Danske Bank |
| Selskabskapital | 500.000 DKK |
| Vedtægter seneste | 10-12-2021 |
Medlem af brancherne
- Forskning og eksperimentel udvikling indenfor bioteknologiNACE6 indeholdende 555 virk.
- Forskning og eksperimentel udvikling indenfor naturvidenskab og teknikNACE3 indeholdende 1.757 virk.
- Videnskabelig forskning og udviklingNACE2 indeholdende 2.048 virk.
- Liberale, videnskabelige og tekniske tjenesteydelserNACE1 indeholdende 86.700 virk.
Formål
Selskabets formål er forskning og udvikling af farmaceutiske produkter for selskaber i Ferring koncernen.
Regnskab
| 2022 | 2021 | 2020 | |
|---|---|---|---|
| Valuta/enhed | 000' DKK | 000' DKK | 000' DKK |
| Omsætning | 1.261.432 +25% | 1.005.468 -4% | 1.051.468 -24% |
| Bruttofortjeneste | 645.934 -36% | 1.005.468 -4% | 1.051.468 -24% |
| Årets resultat | 52.377 +30% | 40.174 -2% | 40.928 +7% |
| Egenkapital | 121.995 +75% | 69.618 -12% | 79.444 -25% |
| Balance | 485.671 +3% | 472.880 +24% | 381.839 +1% |
Ledelsesberetning
Development in activities and financesRevenue and profit for the year
Revenue increased from DKK 1,005 million in 2021 to DKK 1,261 million in 2022.
Other external expenses increased against last year, mainly driven by R&D activities coming back to the level before the covid-19 pandemic, increases in facility cost due to the domicile move, Soundport, March 2022, and IT costs.
Staff costs increased against last year, as average number of full-time employees went up with 12%.
The profit before tax increased from DKK 52.1 million in 2021 to DKK 63,9 million in 2022, driven by the higher revenue.
Investments
Investments amounted to DKK 71,3 million in 2022 against DKK 84 million in 2021. The increase was mainly driven by investments in laboratory capacity in our new domicile, Soundport
Capital resources
Ferring Pharmaceuticals A/S has equity of DKK 121,9 million (2021: DKK 69.6 million). The increase is ex-plained by the results for the year.
Revenue increased from DKK 1,005 million in 2021 to DKK 1,261 million in 2022.
Other external expenses increased against last year, mainly driven by R&D activities coming back to the level before the covid-19 pandemic, increases in facility cost due to the domicile move, Soundport, March 2022, and IT costs.
Staff costs increased against last year, as average number of full-time employees went up with 12%.
The profit before tax increased from DKK 52.1 million in 2021 to DKK 63,9 million in 2022, driven by the higher revenue.
Investments
Investments amounted to DKK 71,3 million in 2022 against DKK 84 million in 2021. The increase was mainly driven by investments in laboratory capacity in our new domicile, Soundport
Capital resources
Ferring Pharmaceuticals A/S has equity of DKK 121,9 million (2021: DKK 69.6 million). The increase is ex-plained by the results for the year.
31-05-2023